{"product_id":"stvn-pestle-analysis","title":"(STVN) Stevanato Group S.p.A. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Stevanato Group S.p.A. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy and investment. The page shows a real preview\/sample of the report so you can judge style and depth; purchase the full version to unlock the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1949 founding, Italy HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFounded in 1949 and based in Piombino Dese, Italy, Stevanato Group sits inside EU policy on trade, industry, and pharma supply chains. Its European plant base makes Italian labor rules, energy costs, and regional aid matter for margins and capacity plans. Italy and EU political stability also affects permits, freight flows, and multiyear capex timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU pharma regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group S.p.A. sells into an EU pharma market shaped by EMA rules, European Commission changes, and 27 national health systems, so qualification and validation can shift fast. \u003c\/p\u003e\n\u003cp\u003eEU GMP Annex 1, tightened in 2023, raised the bar for sterile supply chains and made compliance a plant-level requirement, not just a paperwork task. \u003c\/p\u003e\n\u003cp\u003eWith the EMA centralized route covering all new active substances, regulatory readiness is a sales filter for critical components and machinery, not a back-office cost. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS market dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe United States is the largest pharma market, so Stevanato Group S.p.A. depends on U.S. drug-containment demand. In 2025, U.S. goods imports stayed above $3tn, so tariffs and customs checks can hit margins and slow lead times. Any U.S. reshoring or supply-chain security push can also shift customer sourcing toward local or dual suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic healthcare spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic healthcare spending directly shapes demand for Stevanato Group S.p.A.’s injectable drug and diagnostic packaging, because pharma and medtech orders track hospital and payer budgets. In many OECD markets, health outlays are near 9% to 11% of GDP, so higher state spending can lift production volumes, while austerity or tighter reimbursement can delay new customer launches and capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher budgets support syringe and vial demand.\u003c\/li\u003e\n\u003cli\u003eBudget cuts slow new plant and project starts.\u003c\/li\u003e\n\u003cli\u003eReimbursement pressure can delay customer orders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical supply risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStevanato Group S.p.A. depends on cross-border flows of glass, machinery, and pharma-grade parts, so tariffs, export controls, and border delays can push lead times higher and delay customer capex. A diversified manufacturing and supplier base cuts the risk of a local political shock hitting one plant or lane. In FY2025, that matters more as pharma buyers stay selective on spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCross-border sourcing drives supply risk\u003c\/li\u003e\n\u003cli\u003eGeopolitics can delay shipping and orders\u003c\/li\u003e\n\u003cli\u003eDiversification reduces localized exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy and Health Spending Risks Shape Stevanato’s Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStevanato Group S.p.A. faces political risk from EU and Italian rules on pharma supply, labor, energy, and permits; Annex 1 compliance in 2023 raised sterile-chain standards. U.S. trade policy also matters, with imports above $3tn in 2025 and more customs friction risk.\u003c\/p\u003e\n\u003cp\u003ePublic health budgets drive demand: OECD health spend is near 9% to 11% of GDP, so tighter reimbursement or austerity can slow orders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. goods imports\u003c\/td\u003e\n\u003ctd\u003eAbove $3tn in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD health spend\u003c\/td\u003e\n\u003ctd\u003e9% to 11% of GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU GMP Annex 1\u003c\/td\u003e\n\u003ctd\u003eTightened in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the external forces shaping Stevanato Group S.p.A. across Political, Economic, Social, Technological, Environmental, and Legal factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Stevanato Group PESTLE snapshot to quickly spot external risks and opportunities for planning, presentations, and team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, regulatory filings, and company data to validate Stevanato Group assumptions for fast, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma capex cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group’s machinery and integrated lines rise and fall with pharma capex, so order flow can spike when customers add sterile or fill-finish capacity. In weaker macro periods, those projects are often delayed even if drug demand stays solid, which can soften near-term sales. The risk is real because the company’s 2025 pipeline still depends on when pharma clients release capital budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and energy costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlass-related manufacturing is energy intensive, so higher electricity and fuel prices can move Stevanato Group S.p.A. costs fast. Wage inflation also matters because specialized engineers and production staff are hard to replace, and 2025 wage growth in Europe stayed above pre-2021 norms. If input inflation stays sticky, gross margin can slip when pricing power lags costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUSD and EUR exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group sells across Europe, the U.S., and Asia, so USD and EUR swings hit both revenue translation and input costs. A stronger euro can trim the euro value of non-euro sales, while a weaker euro can lift reported results; even a 5% move in EUR\/USD can shift margins on long supply contracts.\u003c\/p\u003e\n\u003cp\u003eThat makes pricing and hedging important, especially for long-term pharma supply deals where currency moves can outlast contract resets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiologics and injectable growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiologics and sterile injectables keep driving Stevanato Group S.p.A. demand, because these therapies need tight containment, low particulates, and exact delivery. In 2025, biologics still made up a large share of new drug launches, and injectable drugs remained a core route for complex therapies. That supports steady volume growth in vials, cartridges, syringes, and inspection tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMore biologics means more high-value packaging demand.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSterile injectables lift need for vials and syringes.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInspection equipment demand rises with quality rules.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCustomer concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStevanato Group S.p.A. faces customer concentration risk because a few large pharma and biotech clients place big, multi-year orders that can still be uneven. In 2024, revenue was about €1.10bn, so a delay in one major program or plant expansion can move sales fast.\u003c\/p\u003e\n\u003cp\u003eA wider client mix helps smooth earnings across the cycle, while heavy reliance on a small set of programs can make results lumpy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig orders can shift by quarter\u003c\/li\u003e\n\u003cli\u003eFew programs can drive revenue\u003c\/li\u003e\n\u003cli\u003eDiversification lowers earnings swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStevanato's 2025 Sales Ride Pharma Capex Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStevanato Group’s 2025 sales still depend on pharma capex cycles, so delays in sterile or fill-finish builds can soften orders fast. \u003c\/p\u003e\n\u003cp\u003eEnergy, wages, and EUR\/USD swings can pressure margins, since glassmaking is power-heavy and long supply deals reset slowly. \u003c\/p\u003e\n\u003cp\u003eBiologics and sterile injectables keep support for vials, cartridges, syringes, and inspection tools, but customer concentration can make quarterly revenue uneven. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€1.10bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eCapex timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eStevanato Group S.p.A. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Stevanato Group S.p.A. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgeing populations lift demand for chronic-care drugs and injectable therapies, which supports Stevanato Group S.p.A.’s drug containment and delivery systems. The UN says people aged 65+ will reach 1.6 billion by 2050, up from about 771 million in 2022, while safer, easier-to-use devices also matter more as patients and caregivers handle more treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome care and self-administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, more patients and providers prefer therapies that can be used at home, so demand rises for prefillable syringes, auto-injectors, and other user-friendly formats. This helps Stevanato Group S.p.A. because dosing accuracy, simple use, and better adherence matter more outside hospitals. The shift also supports products that cut clinic visits and lower nursing time, which makes self-administration a stronger buying driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient safety expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare buyers demand near-zero contamination risk and consistent drug delivery, so even small packaging defects can hurt patient outcomes and brand trust. For Stevanato Group S.p.A., that makes inspection, traceability, and tight quality control a pricing edge, not just a compliance cost. The company’s 2024 focus on high-value systems reflects this shift as buyers pay for reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic disease keeps demand for Stevanato Group S.p.A.'s primary packaging firm. The IDF says 537 million adults had diabetes in 2021, oncology cases reached 20 million in 2022, and autoimmune disease affects about 5%-8% of people. Many therapies use injections, so high-integrity vials, syringes, and cartridges stay in demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiabetes and cancer drive injection use.\u003c\/li\u003e\n\u003cli\u003eAutoimmune care needs long-term dosing.\u003c\/li\u003e\n\u003cli\u003ePackaging quality stays mission-critical.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust in pharmaceutical supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and regulators expect safe medicines with no gaps in supply, so trust in the pharmaceutical chain is a core social risk for Stevanato Group S.p.A. A single contamination or recall can spread fast, especially in a market where the WHO says 1 in 10 medical products in low- and middle-income countries is substandard or falsified.\u003c\/p\u003e\n\u003cp\u003eThat is why Stevanato Group S.p.A. must keep tight quality control and stable output; in FY2024, it reported about €1.10 billion in revenue, so any supply break can hit both reputation and sales. Reliable packaging and continuity are not just operational goals, they are part of the brand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrust is tied to medicine safety.\u003c\/li\u003e\n\u003cli\u003eRecall risk can damage reputation fast.\u003c\/li\u003e\n\u003cli\u003eQuality systems protect revenue and access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing and Diabetes Drive Stevanato’s Injection Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStevanato Group S.p.A. benefits from ageing populations and more chronic disease, which keep injection use high. The WHO says 1 in 6 people will be 60+ by 2030, and the IDF counted 537 million adults with diabetes in 2021, both supporting demand for safe vials, syringes, and cartridges.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgeing\u003c\/td\u003e\n\u003ctd\u003e1 in 6 by 2030\u003c\/td\u003e\n\u003ctd\u003eMore chronic care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e537 million in 2021\u003c\/td\u003e\n\u003ctd\u003eMore injections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual inspection automation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group makes visual inspection, assembly, and packaging machines, and automation raises line throughput while cutting manual errors in sterile drugs. In 2025, that mattered more as pharma customers kept tightening release standards for high-value injectables, where even a small defect can trigger costly rejects. The same systems also help sites scale with fewer operators, which buyers value when compliance and yield drive the economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlass forming expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group’s glass-forming expertise links its equipment and packaging businesses, and that know-how is hard to copy. Precision processing helps keep dimensional tolerances tight and container integrity high, which matters in sterile drug packaging. In 2025, the company still relied on this niche capability to support differentiated solutions across high-value pharmaceutical applications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-to-use packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharma customers are shifting to nested, ready-to-use containment formats because they cut prep steps and help lower contamination risk in fill-finish lines. This favors Stevanato Group S.p.A. because integrated packaging and process-ready formats fit higher-speed, lower-touch production. The trend also supports demand for standardized RTU systems that can speed scale-up and reduce handling errors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTraceability and data systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTraceability and data systems matter because modern pharma plants must keep complete batch records, line data, and inspection logs to support investigations, batch release, and GMP audits. In a plant serving sterile packaging, digital traceability helps link each vial or syringe to machine settings, vision checks, and operator actions, so defects can be found faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpeeds root-cause checks\u003c\/li\u003e\n\u003cli\u003eSupports batch release decisions\u003c\/li\u003e\n\u003cli\u003eReduces audit gaps\u003c\/li\u003e\n\u003cli\u003eAdds value beyond glass or plastic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eR\u0026amp;D for complex therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiologics and high-potency drugs need tight fit with primary packaging, so Stevanato Group S.p.A. must keep pushing material science and device engineering. The FDA approved 55 novel drugs in 2023, and many were complex therapies, so speed matters when customers need new vials, syringes, and delivery formats. That keeps R\u0026amp;D tied to fast molecule shifts and stricter compatibility tests.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eComplex therapies raise packaging demands.\u003c\/li\u003e\n\u003cli\u003eNew molecules need faster design cycles.\u003c\/li\u003e\n\u003cli\u003eCompatibility testing protects drug stability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStevanato Benefits as Pharma Automation and RTU Demand Rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Stevanato Group S.p.A. gained from pharma’s shift to automation, ready-to-use formats, and tighter traceability in sterile fill-finish lines. Its inspection and packaging systems cut manual errors, lift throughput, and support GMP batch records. Biologics and complex drugs also keep R\u0026amp;D demand high for new vial and syringe formats.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel drugs\u003c\/td\u003e\n\u003ctd\u003e55 in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey tech trend\u003c\/td\u003e\n\u003ctd\u003eAutomation, RTU, traceability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU MDR and IVDR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEU MDR (2017\/745) and IVDR (2017\/746) raise the bar on testing, technical files, and post-market surveillance, so Stevanato Group faces longer validation cycles and higher compliance cost. MDR has applied since 26 May 2021 and IVDR since 26 May 2022, and any gap in evidence can slow CE marking and delay launches. For glass vials, syringes, and diagnostics packaging, missed updates can also restrict EU market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP and ISO 13485\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharma and device customers demand GMP and ISO 13485:2016 proof before qualification. ISO 13485 is the core medical-device QMS standard, and FDA’s QMSR aligns 21 CFR Part 820 with it from 2 Feb 2026. For Stevanato Group S.p.A., audit success and valid certification are tied to the right to supply regulated buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group’s containment and delivery components sit close to the drug product, so a defect can affect safety and patient outcomes. In 2025, the FDA logged thousands of medical product recalls each year across pharma and devices, showing how fast small failures can become claims, recalls, or lost customers. That is why testing, traceability, and risk files are legally critical, not just quality controls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStevanato Group S.p.A. relies on proprietary machinery and product designs to protect margins and support premium pricing. In FY2024, net revenues were about €1.1bn, so even modest IP leakage can matter. Strong patent and trade secret protection can also support licensing, but weak enforcement in some markets raises copycat risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtects pricing power and margins\u003c\/li\u003e\n\u003cli\u003eSupports licensing income\u003c\/li\u003e\n\u003cli\u003eCopying risk rises where enforcement is weak\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData privacy and cyber rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStevanato Group S.p.A. relies on digital systems for production, customer access, and quality records, so privacy and cyber controls are a legal issue, not just an IT one. Under GDPR, serious breaches can bring fines up to €20 million or 4% of global turnover, whichever is higher. Cyber lapses can also force downtime and damage trust with pharma customers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDPR fines: up to €20 million or 4% turnover\u003c\/li\u003e\n\u003cli\u003eNIS2 adds stricter reporting and security duties\u003c\/li\u003e\n\u003cli\u003eBreaches can halt operations and hurt reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory compliance is Stevanato’s key legal risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for Stevanato Group S.p.A. is driven by MDR\/IVDR, GMP\/ISO 13485, IP rights, and privacy law. EU MDR has applied since 26 May 2021 and IVDR since 26 May 2022; FDA’s QMSR aligns with ISO 13485 from 2 Feb 2026, so compliance gaps can delay CE marking, U.S. supply, and customer qualification.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU MDR\u003c\/td\u003e\n\u003ctd\u003e26 May 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU IVDR\u003c\/td\u003e\n\u003ctd\u003e26 May 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA QMSR\u003c\/td\u003e\n\u003ctd\u003e2 Feb 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR\u003c\/td\u003e\n\u003ctd\u003eUp to €20m or 4% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy-intensive glass production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlass furnaces run above 1,500°C, so energy use is one of Stevanato Group S.p.A.'s biggest operating and emissions drivers. \u003c\/p\u003e\n\u003cp\u003eThat means every gain in efficiency can cut fuel costs and lower Scope 1 and 2 emissions at the same time. \u003c\/p\u003e\n\u003cp\u003eUsing lower-carbon power and cleaner heat also helps meet stricter rules and strengthens cost competitiveness. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScope 1 and 2 emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScope 1 and 2 emissions are a live risk for Stevanato Group S.p.A. because pharma buyers now ask suppliers for carbon data, and lower emissions can help win tenders and long-term contracts. With EU CSRD reporting now hitting FY2025 for many large groups, factories must track fuel and electricity use more tightly. That makes cleaner plants a commercial issue, not just a compliance one.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWaste and recycling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStevanato Group S.p.A.’s primary packaging and machine production create metal, glass, plastic, and scrap streams, so waste control directly affects cost and compliance. In the EU, packaging waste reached 189.1 kg per person in 2022, while the circular material use rate was only 11.5%, showing why recycling and recovery matter. Circular-economy practices are now a clear expectation in European manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWater and process controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWater and process controls matter because Stevanato Group S.p.A.’s precision glass and drug-delivery lines depend on stable clean-room conditions, tight wastewater handling, and permit compliance. Efficient process design cuts water use, lowers discharge load, and reduces the risk of local resource limits slowing production or triggering permit changes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControl water intake.\u003c\/li\u003e\n\u003cli\u003eMonitor wastewater quality.\u003c\/li\u003e\n\u003cli\u003eReduce permit risk.\u003c\/li\u003e\n\u003cli\u003eProtect clean-room output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate and supply disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtreme weather can hit Stevanato Group S.p.A.'s logistics, utilities, and suppliers at the same time, and that matters because global insured natural catastrophe losses were about $140 billion in 2024. Pharma supply chains are extra exposed: even short transport delays can break temperature control and trigger scrap or rerouting costs.\u003c\/p\u003e\n\u003cp\u003eResilient sourcing, dual suppliers, and higher safety stock help cut this risk, especially for temperature-sensitive products. For one line: weather risk is supply risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeat, floods, storms disrupt deliveries.\u003c\/li\u003e\n\u003cli\u003eCold-chain delays can damage shipments.\u003c\/li\u003e\n\u003cli\u003eInventory buffers protect service levels.\u003c\/li\u003e\n\u003cli\u003eDual sourcing reduces single-point failure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStevanato’s Climate Risks: Energy, Waste, and Supply Chain Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnergy, emissions, waste, water, and weather are the main environmental pressure points for Stevanato Group S.p.A. Glass furnaces above 1,500°C make power use and Scope 1-2 emissions a direct cost and reporting issue.\u003c\/p\u003e\n\u003cp\u003eEU packaging waste hit 189.1 kg per person in 2022, while circular material use was 11.5%, so recycling and scrap control matter.\u003c\/p\u003e\n\u003cp\u003eExtreme weather can also disrupt pharma supply chains and cold-chain deliveries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003eFurnaces above 1,500°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003e189.1 kg EU packaging waste per person\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCircularity\u003c\/td\u003e\n\u003ctd\u003e11.5% EU material use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235124977929,"sku":"stvn-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/stvn-pestle-analysis.webp?v=1785732822","url":"https:\/\/dcfanalyst.com\/products\/stvn-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}